quinpirole has been researched along with Parkinson Disease, Secondary in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.63) | 18.7374 |
| 1990's | 19 (59.38) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ | 1 |
| Cimini, MG; Haas, JV; Nichols, NF; Staton, BA; Svensson, KA; Tedroff, J | 1 |
| Bédard, PJ; Grégoire, L; Samadi, P | 1 |
| Bibbiani, F; Chase, TN; Collins, MA; Kielaite, A; Oh, JD; Smith, C | 1 |
| Bazinet, RP; Bhattacharjee, AK; Chang, L; Meister, LM; Rapoport, SI; White, L | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Johnson, BJ; Peacock, V; Schneider, JS | 1 |
| Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD | 1 |
| Erol, DD; Gnanalingham, KK; Hunter, AJ; Jenner, P; Marsden, CD; Smith, LA | 1 |
| Drukarch, B; Goosen, C; Sahadat, MC; Stoof, JC; Vermeulen, RJ; Wolters, EC | 1 |
| Bennett, JP; Richard, MG | 1 |
| Misu, Y; Okumura, F; Sato, K; Ueda, H | 2 |
| Bernardi, G; Calabresi, P; Mercuri, NB; Sancesario, G | 1 |
| Kuno, S; Mizuta, E; Sasa, M; Yoshida, O; Yoshimura, N | 1 |
| Björklund, A; Duan, WM; Jödicke, A; Knappe, U; Nikkhah, G | 1 |
| Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K | 1 |
| Andringa, G; Cools, AR; Drukarch, B; Stoof, JC; Vermeulen, RJ | 1 |
| Brotchie, JM; Crossman, AR; Maneuf, YP | 1 |
| Brotchie, JM; Fox, SH; Moser, B | 1 |
| Jackson, MJ; Jenner, P; Kanda, T; Kase, H; Kuwana, Y; Nakamura, J; Pearce, RK; Smith, LA | 1 |
| Andringa, G; Cools, AR; Drukarch, B; Renier, WO; Stoof, JC; Vermeulen, RJ | 1 |
| Andbjer, B; Fuxe, K; Kehr, J; Strömberg, I | 1 |
| Bédard, PJ; Boucher, R; Gomez-Mancilla, B | 1 |
| Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF | 1 |
| Close, SP; Elliott, PJ; Walsh, DM | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Bédard, PJ; Boucher, R | 1 |
| Schneider, JS | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Jenner, P; Marsden, CD | 1 |
| Jenner, P; Marsden, CD; Nomoto, M | 1 |
1 review(s) available for quinpirole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
31 other study(ies) available for quinpirole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats | 2018 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2002 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 2003 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Haplorhini; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Rotarod Performance Test; Time Factors | 2005 |
In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Arachidonic Acid; Autoradiography; Blood Pressure; Body Temperature; Dextroamphetamine; Dopamine; Dopamine Agonists; Dopamine Uptake Inhibitors; Heart Rate; Hydroxydopamines; Infusions, Intra-Arterial; Infusions, Intravenous; Parkinson Disease, Secondary; Quinpirole; Radiopharmaceuticals; Rats; Receptors, Presynaptic; Signal Transduction; Sympatholytics; Synapses | 2007 |
Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Dopamine Agonists; Globus Pallidus; Hydroxydopamines; Male; Neuroprotective Agents; Parkinson Disease, Secondary; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Rotation; Stereotyped Behavior; Sympathectomy, Chemical; Triazoles | 2008 |
Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Ergolines; Functional Laterality; Macaca mulatta; Male; Parkinson Disease, Secondary; Phenanthridines; Quinpirole; Raclopride; Receptors, Dopamine D1; Rotation; Salicylamides | 1995 |
The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Behavior, Animal; Callithrix; Dopamine Agonists; Ergolines; Female; In Vitro Techniques; Male; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D1; Species Specificity | 1995 |
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Binding, Competitive; Callithrix; Dopamine Agonists; Ergolines; In Vitro Techniques; Male; Parkinson Disease, Secondary; Quinpirole; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone | 1995 |
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Macaca mulatta; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Psychomotor Performance; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra | 1994 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Ergolines; Haloperidol; Hydrazines; Kinetics; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reference Values | 1994 |
Supersensitization of intrastriatal dopamine receptors involved in opposite regulation of acetylcholine release in Parkinson's model rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetylcholine; Animals; Benzazepines; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Ergolines; Male; Microdialysis; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride; Sympathectomy, Chemical | 1994 |
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Ergolines; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Quinpirole; Rats; Rats, Wistar; Substantia Nigra; Synaptic Membranes; Tetrodotoxin | 1993 |
The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dopamine Agents; Ergolines; Macaca fascicularis; Male; Parkinson Disease, Secondary; Quinpirole; Reflex; Urinary Bladder; Urination | 1993 |
Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Caudate Nucleus; Corpus Striatum; Denervation; Dextroamphetamine; Dopamine; Ergolines; Feeding Behavior; Female; Fetal Tissue Transplantation; Forelimb; Motor Activity; Orientation; Oxidopamine; Parkinson Disease, Secondary; Putamen; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Regression Analysis; Rotation; Substantia Nigra | 1993 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Ergolines; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1995 |
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes | 1997 |
Dopamine receptor subtypes as targets for the pharmacotherapy of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzazepines; Dopamine Agonists; Haplorhini; Levodopa; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1 | 1998 |
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Locomotion; Male; Morpholines; Naphthalenes; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Reserpine; Rimonabant | 1997 |
Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agonists; Excitatory Amino Acid Antagonists; Indoles; Kynurenic Acid; Locomotion; Male; Microinjections; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Substantia Nigra; Sympatholytics; Urea | 1998 |
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Carbidopa; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Quinpirole; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2000 |
The validity of the pretreated, unilaterally MPTP-treated monkeys as a model of Parkinson's disease: a detailed behavioural analysis of the therapeutic and undesired effects of the D2 agonist quinpirole and the D1 agonist SKF 81297.
Topics: Animals; Arm; Behavior, Animal; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Electroencephalography; Macaca mulatta; Male; Motor Activity; Movement; MPTP Poisoning; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Reproducibility of Results | 1999 |
Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
Topics: Animals; Apomorphine; Benzazepines; Brain Tissue Transplantation; Corpus Striatum; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Fetal Tissue Transplantation; Glutamic Acid; Membrane Potentials; Mesencephalon; Microdialysis; Microelectrodes; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2000 |
Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electromyography; Ergolines; Female; Indoles; Injections, Subcutaneous; Macaca fascicularis; Parkinson Disease, Secondary; Phenanthridines; Quinpirole; Tremor | 1992 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Relationship, Drug; Electromyography; Ergolines; Ethosuximide; Female; Macaca fascicularis; Neurologic Examination; Parkinson Disease, Secondary; Quinpirole; Tremor; Verapamil | 1992 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Levodopa; Male; Movement; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Ergolines; Female; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1; Sulpiride | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzazepines; Callitrichinae; Ergolines; Female; Male; Parkinson Disease, Secondary; Pyridines; Quinpirole; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1985 |